Signaling pathways
-
BA6947 LicogliflozinSummary: An inhibitor of sodium-glucose cotransporter protein (and). - BA6948 KGA-2727Summary: KGA-2727 is a selective, high affinity and orally active inhibitor.
- BA6949 VelagliflozinSummary: Velagliflozin is an orally available sodium-glucose cotransporter protein 2 inhibitor with antidiabetic activity.
- BA6950 EnavogliflozinSummary: Enavogliflozin (DWP-16001) acts as an antidiabetic active molecule.
- BA6951 TianagliflozinSummary: Tianagliflozin is a sodium/glucose cotransporter protein 2 inhibitor.
-
BA6952 RemogliflozinSummary: Remogliflozin is a potent and selective inhibitor of the human and rat sodium-glucose cotransporter 2. - BA6953 T-1095Summary: T-1095 is a selective and orally active inhibitor of Na-glucose cotransporter proteins with 22.8 μM and 2.3 μM against human SGLT1 and SGLT2, respectively.
- BA6954 LuseogliflozinSummary: Luseogliflozin (TS071) is a potent, selective, and orally active inhibitor of sodium-glucose cotransporter protein 2.
- BA6955 HSK0935Summary: HSK0935 is a potent, highly selective, orally available inhibitor.
- BA6956 LTGO-33Summary: LTGO-33 is a potent and selective voltage-gated sodium channel inhibitor.